Alkermes Inc.

Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013.
Diabetes Week; 12/14/2009; 1111 words; ...the launch of several novel agents like Amylin/Eli Lilly/Alkermes's Byetta LAR (see also Type 2 Diabetes). "Throughout our...Glargine Recombinant, Januvia, Lantus, Levemir, Merck & Company Inc., Non-insulin Dependent Diabetes Mellitus, Novartis AG...

Alkermes to Webcast Presentation at the Deutsche Bank Biotech Boston Confab.
Health & Beauty Close-Up; 12/11/2009; 644 words; Alkermes, Inc. has announced that its corporate presentation...under the investor relations tab at alkermes.com. The presentation will be archived for 14 days. Alkermes, Inc. is a fully integrated biotechnology...

ALKERMES FILES 10-Q (QUARTERLY REPORT)
US Fed News Service, Including US State News; 12/8/2009; 285 words; WASHINGTON, Dec. 8 -- Alkermes Inc., Cambridge, Mass., has filed a Form 10-Q on Nov. 5 for the second quarter ending Sept. 30 with the U.S. Securities...

Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank Biotech Boston Confab.
Business Wire; 12/8/2009; 735 words; CAMBRIDGE, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) announced...investor relations tab at www.alkermes.com. The presentation will be archived for 14 days. Alkermes, Inc. is a fully integrated biotechnology...

Acceleron Pharma Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at the 51st Annual Meeting of the American Society of Hematology.
Business Wire; 12/8/2009; 955 words; ...Increase Red Blood Cells CAMBRIDGE, Mass. -- Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics...investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities...